GFAP ELISA Kits
GFAP ELISA kits are designed to detect and quantify GFAP concentrations in diverse sample types, including serum, plasma, cerebrospinal fluid (CSF), tissue homogenates, and cell culture supernatants. These kits typically employ a sandwich ELISA format, wherein specific antibodies capture GFAP, and detection is facilitated through enzyme-linked secondary antibodies, culminating in a measurable signal proportional to GFAP concentration.
Key Components:
- Pre-coated Microplate: Wells pre-coated with anti-GFAP antibodies to capture the target protein.
- Standards and Controls: Known concentrations of GFAP to generate a standard curve and validate assay performance.
- Detection Antibodies: Enzyme-conjugated antibodies specific to GFAP for signal generation.
- Substrate Solution: Reacts with the enzyme to produce a detectable signal, typically colorimetric.
Applications:
- Neuroscience Research: Investigating astrocyte function, neuroinflammation, and the role of GFAP in neurodegenerative diseases such as Alzheimer's and Parkinson's.
- Clinical Diagnostics: Assessing GFAP levels as potential biomarkers for traumatic brain injury, stroke, and other neurological disorders.
- Pharmaceutical Development: Evaluating the efficacy of therapeutic agents targeting astrocytic activity or neuroinflammatory pathways.
Examples of GFAP ELISA Kits:
- Sigma-Aldrich GFAP ELISA Kit (NS830): A sandwich ELISA designed for the quantitation of GFAP in human, mouse, and rat samples, including serum, plasma, CSF, cell culture, and tissue homogenates.
- Invitrogen Human GFAP ELISA Kit: A solid-phase sandwich ELISA intended to measure GFAP levels in human serum and plasma, with a sensitivity of 9.38 pg/mL and an assay range of 15.63–1000 pg/mL.
- Abcam Human GFAP ELISA Kit (ab223867): A single-wash 90-minute sandwich ELISA designed for the quantitative measurement of GFAP protein in tissue extracts, utilizing proprietary SimpleStep ELISA® technology.
By providing reliable and quantitative measurements of GFAP, ELISA kits are indispensable tools in advancing our understanding of astrocytic function and facilitating the diagnosis and management of neurological disorders.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|